BioTuesdays

Tag - NKTK

Nkarta Therapeutics

Stifel starts Nkarta at buy; PT $41

Stifel launched coverage of Nkarta (NASDAQ:NKTX) with a “buy” rating and 12-month target price of $41. The stock closed at $26.58 on Aug. 3. Nkarta is focused on the discovery, development, and potential...